You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
從創新藥擴散到CXO!藥明康德上半年業績狂飆,帶動“藥明含量”近20%的創新藥ETF天弘(517380)大升2.65%,位居同類產品第一
今日CXO板塊強勢上揚,創新藥ETF天弘(517380)第一權重股成分股藥明康德H股飆升11%,A股升近10%,藥明合聯升超12%,帶動ETF上升2.65%,升幅位居全市場醫藥類ETF第一。消息面上,藥明康德發盈喜,預計2025年上半年營業收入約207.99億元,同比增長約20.64%;預計歸屬於公司股東的淨利潤約85.61億元,同比增長約101.92%,營收利潤雙增長,盈利能力持續優化,股價自去年低點以來飆升超170%。全市場獨家品種·創新藥ETF天弘(517380)及聯接基金(A類014564, C類014565)是全市場唯一跟蹤恒生滬深港創新藥精選50指數的ETF,實現了A股+港股、創新藥+CXO全面覆蓋,權重股“藥明系含量”極高,第一權重股藥明康德A股(10.23%)、第五大權重股藥明生物(6.6%)、藥明康德H股(1.93%)、藥明合聯(0.9%)。創新藥ETF天弘(517380)連續4日迎來資金淨流入,近一週合計吸金3885.16萬元生物醫藥ETF(159859)及聯接基金(A類011040, C類011041)是同標的規模第一、流動性最好的產品,年初至今升幅居標的第一,其跟蹤生物醫藥指數,均衡佈局醫藥板塊,覆蓋創新藥、疫苗、血製品等細分品種。中金認為,2025年,流動性預期樂觀以及國內AI等技術突破等都導向以及創新藥為代表的醫藥科技類資產更適合今年的投資環境。該行指出,受益於下游創新藥板塊今年的積極表現,一二級新藥投融資環境改善,對以內需CRO和科研上游為代表的供應鏈體系有較為積極的訂單改善邊際影響。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account